Earnings analysis · 10-Q
BLSM earnings analysis
Filed September 18, 2026 · Our reading of the company's report
The latest report
BlossomHill reported Q2 2026 EPS of $(8.75), substantially worse than the $(0.77) consensus estimate, while revenue and detailed income-statement trend data were not disclosed in the provided filing text. The August IPO…
Read full summary
BlossomHill reported Q2 2026 EPS of $(8.75), substantially worse than the $(0.77) consensus estimate, while revenue and detailed income-statement trend data were not disclosed in the provided filing text. The August IPO generated approximately $151.7 million of net proceeds, lifting cash resources to an estimated runway into Q2 2028, but the company remains loss-making, with a six-month net loss of $44.8 million and accumulated deficit of approximately $179.8 million. The pipeline has regulatory momentum, including Fast Track and orphan drug designations, but remains early-stage and exposed to clinical, safety, financing and manufacturing risks.
Reported figures
- Earnings per share
- $-8.75
What stood out
-
IPO materially strengthens liquidity
The company reported Q2 2026 EPS of $(8.75), materially below the $(0.77) consensus estimate. Revenue was not disclosed in the provided filing text.
-
$151.7M of net IPO proceeds
BlossomHill received aggregate gross IPO proceeds of approximately $168.3 million and net proceeds of approximately $151.7 million after $16.6 million of offering expenses.
-
Runway extends into Q2 2028
As of June 30, 2026, cash and cash equivalents totaled $95.4 million. Management estimates existing cash plus IPO proceeds will fund operations into Q2 2028.
-
Regulatory designations advance pipeline
BH-30236 received FDA orphan drug designation for AML in March 2026, while BH-30643 received FDA Fast Track designation in August 2026 for EGFR C797S-positive NSCLC.
-
Pipeline remains focused and early-stage
The company had 69 full-time employees as of June 30, 2026, supporting development of two clinical-stage candidates and one preclinical pan-KRAS candidate.
What to watch
-
Losses remain substantial and rising
The company reported a six-month 2026 net loss of $44.8 million and an accumulated deficit of approximately $179.8 million as of June 30, 2026. It anticipates substantial and increasing losses for the foreseeable future.
-
Clinical pipeline is early-stage
BlossomHill has not completed any pivotal or late-stage clinical trials and has no product candidates approved for commercial sale. BH-30643 and BH-30236 remain in early clinical development, while BH-501284 is preclinical.
-
Additional financing remains necessary
Management states that additional capital will be required to complete clinical development, despite estimating current resources fund operations into Q2 2028. Future equity financing could dilute holders, while failure to raise capital could delay, reduce or terminate development programs.
-
Clinical safety risks could delay trials
The company reported treatment-related toxicities in ongoing trials, including high-grade EGFR wild-type toxicity, liver-function abnormalities and pneumonitis for BH-30643, and high-grade diarrhea and grade 2 differentiation syndrome for BH-30236.
-
China-linked supply chain exposure
The company relies on third-party manufacturers and currently has no long-term commitments or supply agreements with them. APIs for BH-30643 and BH-30236 are manufactured in China, creating exposure to supply disruptions, tariffs and trade restrictions.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management estimates that cash and cash equivalents of $95.4 million as of June 30, 2026, together with $151.7 million of net IPO proceeds, will fund projected operating expenses and capital expenditures into the second quarter of 2028.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.